TEM is trading at $45.94 (-5.2%) during Tuesday's session, extending losses following its May 7 earnings report as macro headwinds weigh on the biotech and AI sectors.
- The stock has declined 7.5% since its earnings release, despite management raising full-year revenue guidance to a range of $1.59B–$1.60B.
- Today's drop aligns with a broader market retreat—with the NASDAQ down 1.76%—driven by hotter-than-expected April CPI data (3.8% vs. 3.7% forecast) and escalating Middle East geopolitical tensions.
- Investors are currently reassessing risk appetite and interest rate-cut expectations, creating significant headwinds for high-growth AI and biotechnology firms.